{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:12:36Z","timestamp":1792156356713,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40263-025-01262-9","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T11:42:16Z","timestamp":1773488536000},"page":"803-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct05875974","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-5654","authenticated-orcid":false,"given":"David T.","family":"Plante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-7751","authenticated-orcid":false,"given":"Alyssa","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8729-5224","authenticated-orcid":false,"given":"Logan D.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0886-1707","authenticated-orcid":false,"given":"Deborah A.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9564-0901","authenticated-orcid":false,"given":"Teresa L.","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-5896","authenticated-orcid":false,"given":"Douglas S.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Todd","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-0858","authenticated-orcid":false,"given":"Chad M.","family":"Ruoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"1262_CR1","volume-title":"International classification of sleep disorders\u2014third edition, text revision","author":"American Academy of Sleep Medicine","year":"2023","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders\u2014third edition, text revision. Darien: American Academy of Sleep Medicine; 2023."},{"key":"1262_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101306","volume":"52","author":"GJ Lammers","year":"2020","unstructured":"Lammers GJ, Bassetti CLA, Dolenc-Groselj L, Jennum PJ, Kallweit U, Khatami R, et al. Diagnosis of central disorders of hypersomnolence: a reappraisal by European experts. Sleep Med Rev. 2020;52:101306. https:\/\/doi.org\/10.1016\/j.smrv.2020.101306.","journal-title":"Sleep Med Rev"},{"issue":"7","key":"1262_CR3","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.5664\/jcsm.11566","volume":"21","author":"LD Schneider","year":"2025","unstructured":"Schneider LD, Cairns A, Ruoff C, Bogan RK. Current knowledge on the pathophysiology of idiopathic hypersomnia and potential mechanisms of action for low-sodium oxybate treatment. J Clin Sleep Med. 2025;21(7):1245\u201360. https:\/\/doi.org\/10.5664\/jcsm.11566.","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"1262_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa044","volume":"43","author":"R Fronczek","year":"2020","unstructured":"Fronczek R, Arnulf I, Baumann CR, Maski K, Pizza F, Trotti LM. To split or to lump? Classifying the central disorders of hypersomnolence. Sleep. 2020;43(8):zsaa044. https:\/\/doi.org\/10.1093\/sleep\/zsaa044.","journal-title":"Sleep"},{"key":"1262_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2022.101709","volume":"66","author":"Y Dauvilliers","year":"2022","unstructured":"Dauvilliers Y, Bogan RK, Arnulf I, Scammell TE, St Louis EK, Thorpy MJ. Clinical considerations for the diagnosis of idiopathic hypersomnia. Sleep Med Rev. 2022;66:101709.","journal-title":"Sleep Med Rev"},{"issue":"8","key":"1262_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.5664\/jcsm.8482","volume":"16","author":"J Acquavella","year":"2020","unstructured":"Acquavella J, Mehra R, Bron M, Suomi JMH, Hess GP. Prevalence of narcolepsy, other sleep disorders, and diagnostic tests from 2013\u20132016: insured patients actively seeking care. J Clin Sleep Med. 2020;16(8):1255\u201363.","journal-title":"J Clin Sleep Med"},{"key":"1262_CR7","doi-asserted-by":"crossref","unstructured":"Saad R, Black J, Bogan RK, Jensen ET, Lillaney P, Prince P, Estrin A, Whalen M, Macfadden W, Ni W, Plante DT, editors. Diagnosed prevalence of idiopathic hypersomnia among adults in the United States [poster]. Annual meeting of the academy of managed care pharmacy nexus; 2023 October 16\u201319; Orlando, FL.","DOI":"10.1093\/sleep\/zsad077.0838"},{"issue":"2","key":"1262_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207994","volume":"102","author":"DT Plante","year":"2024","unstructured":"Plante DT, Hagen EW, Barnet JH, Mignot E, Peppard PE. Prevalence and course of idiopathic hypersomnia in the Wisconsin Sleep Cohort study. Neurology. 2024;102(2):e207994. https:\/\/doi.org\/10.1212\/WNL.0000000000207994.","journal-title":"Neurology"},{"issue":"1","key":"1262_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2011.1240","volume":"69","author":"MM Ohayon","year":"2012","unstructured":"Ohayon MM, Dauvilliers Y, Reynolds CF 3rd. Operational definitions and algorithms for excessive sleepiness in the general population: implications for DSM-5 nosology. Arch Gen Psychiatry. 2012;69(1):71\u20139. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.1240.","journal-title":"Arch Gen Psychiatry"},{"key":"1262_CR10","unstructured":"Whalen M, Roy B, Steininger T, Dronamraju N, Enson D, editors. Patient perspective on idiopathic hypersomnia: impact on quality of life and satisfaction with the diagnostic process and management [poster 157]. Annual meeting of the associated professional sleep societies; 2022 June 4\u20138, 2022; Charlotte, NC."},{"key":"1262_CR11","unstructured":"Alexander JK, Markt SC, Whalen M, Carlyle M, Drachenberg C, White J, Casstevens C, Dick LL, Beaty S, Ruoff CM, editors. Prevalence and severity of sleep inertia among individuals with idiopathic hypersomnia [poster 557]. Annual meeting of the associated professional sleep societies; 2025 June 8\u201311, 2025; Seattle, WA."},{"key":"1262_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.smrv.2016.08.005","volume":"35","author":"LM Trotti","year":"2017","unstructured":"Trotti LM. Waking up is the hardest thing i do all day: sleep inertia and sleep drunkenness. Sleep Med Rev. 2017;35:76\u201384. https:\/\/doi.org\/10.1016\/j.smrv.2016.08.005.","journal-title":"Sleep Med Rev"},{"issue":"3","key":"1262_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jsmc.2022.06.016","volume":"17","author":"I Arnulf","year":"2022","unstructured":"Arnulf I, Leu-Semenescu S, Dodet P. Precision medicine for idiopathic hypersomnia. Sleep Med Clin. 2022;17(3):379\u201398. https:\/\/doi.org\/10.1016\/j.jsmc.2022.06.016.","journal-title":"Sleep Med Clin"},{"key":"1262_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.sleep.2020.08.034","volume":"75","author":"LM Trotti","year":"2020","unstructured":"Trotti LM, Ong JC, Plante DT, Friederich Murray C, King R, Bliwise DL. Disease symptomatology and response to treatment in people with idiopathic hypersomnia: initial data from the Hypersomnia Foundation Registry. Sleep Med. 2020;75:343\u20139. https:\/\/doi.org\/10.1016\/j.sleep.2020.08.034.","journal-title":"Sleep Med"},{"key":"1262_CR15","volume-title":"Idiopathic hypersomnia. International classification of sleep disorders","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. Idiopathic hypersomnia. International classification of sleep disorders, 3rd ed. Darien: American Academy of Sleep Medicine; 2014.","edition":"3"},{"key":"1262_CR16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Publishing; 2013.","edition":"5"},{"issue":"6","key":"1262_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/ana.23818","volume":"73","author":"MM Ohayon","year":"2013","unstructured":"Ohayon MM, Reynolds CF 3rd, Dauvilliers Y. Excessive sleep duration and quality of life. Ann Neurol. 2013;73(6):785\u201394. https:\/\/doi.org\/10.1002\/ana.23818.","journal-title":"Ann Neurol"},{"key":"1262_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/NSS.S396641","volume":"15","author":"J Stevens","year":"2023","unstructured":"Stevens J, Schneider LD, Husain A, Ito D, Fuller DS, Zee PC, et al. Impairment in functioning and quality of life in patients with idiopathic hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (ARISE). Nat Sci Sleep. 2023;15:593\u2013606.","journal-title":"Nat Sci Sleep"},{"key":"1262_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.sleep.2020.10.014","volume":"76","author":"HB Wasling","year":"2020","unstructured":"Wasling HB, Bornstein A, Wasling P. Quality of life and procrastination in post-H1N1 narcolepsy, sporadic narcolepsy and idiopathic hypersomnia, a Swedish cross-sectional study. Sleep Med. 2020;76:104\u201312. https:\/\/doi.org\/10.1016\/j.sleep.2020.10.014.","journal-title":"Sleep Med"},{"issue":"2","key":"1262_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.sleep.2011.07.014","volume":"13","author":"A Ozaki","year":"2012","unstructured":"Ozaki A, Inoue Y, Hayashida K, Nakajima T, Honda M, Usui A, et al. Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between patients on psychostimulants, drug-na\u00efve patients and the general Japanese population. Sleep Med. 2012;13(2):200\u20136. https:\/\/doi.org\/10.1016\/j.sleep.2011.07.014.","journal-title":"Sleep Med"},{"issue":"2","key":"1262_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5664\/jcsm.9682","volume":"18","author":"AL Rassu","year":"2022","unstructured":"Rassu AL, Evangelista E, Barateau L, Chenini S, Lopez R, Jaussent I, et al. Idiopathic hypersomnia severity scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. J Clin Sleep Med. 2022;18(2):617\u201329. https:\/\/doi.org\/10.5664\/jcsm.9682.","journal-title":"J Clin Sleep Med"},{"key":"1262_CR22","unstructured":"Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII [prescribing information]. Palo Alto: Jazz Pharmaceuticals, Inc.; 2025."},{"issue":"19","key":"1262_CR23","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/nejm199511093331917","volume":"333","author":"A Szarfman","year":"1995","unstructured":"Szarfman A, Kuchenberg T, Soreth J, Lajmanovich S. Declaring the sodium content of drug products. N Engl J Med. 1995;333(19):1291. https:\/\/doi.org\/10.1056\/nejm199511093331917.","journal-title":"N Engl J Med"},{"key":"1262_CR24","unstructured":"US Food and Drug Administration. Clinical review for Binosto, NDA 202344; 2012 [February 7, 2012]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202344Orig1s000MedR.pdf."},{"key":"1262_CR25","unstructured":"US Food and Drug Administration. Quantitative labeling of sodium, potassium, and phosphorus for human over-the-counter and prescription drug products. Guidance for industry. Silver Spring, MD: US Food and Drug Administration; 2022 [17 September 2025]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug."},{"key":"1262_CR26","unstructured":"Xywav [Canadian product monograph including patient medication information]. Dublin, Ireland: Jazz Pharmaceuticals Ireland Ltd.; 2023."},{"issue":"1","key":"1262_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1474-4422(21)00368-9","volume":"21","author":"Y Dauvilliers","year":"2022","unstructured":"Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, Morse AM, Sonka K, Thorpy MJ, et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022;21(1):53\u201365.","journal-title":"Lancet Neurol"},{"key":"1262_CR28","doi-asserted-by":"crossref","unstructured":"Morse AM, Chen A, Steininger TL, Macfadden W. Effects of lower-sodium oxybate on 24-hour total sleep time: data from a phase 3 clinical study in adults with idiopathic hypersomnia [poster 119]. Biennial World Sleep; 2022 March 11-16, 2022; Rome, Italy.","DOI":"10.1212\/WNL.0000000000203244"},{"key":"1262_CR29","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2147\/NSS.S369122","volume":"14","author":"MJ Thorpy","year":"2022","unstructured":"Thorpy MJ, Arnulf I, Foldvary-Schaefer N, Morse AM, \u0160onka K, Chandler P, et al. Efficacy and safety of lower-sodium oxybate in an open-label titration period of a phase 3 clinical study in adults with idiopathic hypersomnia. Nat Sci Sleep. 2022;14:1901\u201317.","journal-title":"Nat Sci Sleep"},{"issue":"3","key":"1262_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s40120-024-00607-8","volume":"13","author":"AM Morse","year":"2024","unstructured":"Morse AM, Bogan RK, Roy A, Thorpy MJ. Dosing optimization of low-sodium oxybate in narcolepsy and idiopathic hypersomnia in adults: consensus recommendations. Neurol Ther. 2024;13(3):785\u2013807. https:\/\/doi.org\/10.1007\/s40120-024-00607-8.","journal-title":"Neurol Ther"},{"issue":"4","key":"1262_CR31","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40120-025-00745-7","volume":"14","author":"DA Nichols","year":"2025","unstructured":"Nichols DA, Steininger TL, Fuller DS, Kirby MT, Barker EC, Whalen M, et al. A patient-centric clinical trial design to comprehensively evaluate low-sodium oxybate in people with idiopathic hypersomnia or narcolepsy. Neurol Ther. 2025;14(4):1705\u201327. https:\/\/doi.org\/10.1007\/s40120-025-00745-7.","journal-title":"Neurol Ther"},{"key":"1262_CR32","volume-title":"The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, version 3","author":"RB Berry","year":"2023","unstructured":"Berry RB, Quan SF, Abreu AR, Bibbs ML, DelRosso L, Harding SM, et al. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, version 3. Darien: American Academy of Sleep Medicine; 2023."},{"issue":"8","key":"1262_CR33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/sleep\/17.8.703","volume":"17","author":"MW Johns","year":"1994","unstructured":"Johns MW. Sleepiness in different situations measured by the Epworth Sleepiness Scale. Sleep. 1994;17(8):703\u201310. https:\/\/doi.org\/10.1093\/sleep\/17.8.703.","journal-title":"Sleep"},{"issue":"15","key":"1262_CR34","doi-asserted-by":"publisher","first-page":"e1754","DOI":"10.1212\/wnl.0000000000007264","volume":"92","author":"Y Dauvilliers","year":"2019","unstructured":"Dauvilliers Y, Evangelista E, Barateau L, Lopez R, Chenini S, Delbos C, et al. Measurement of symptoms in idiopathic hypersomnia: the Idiopathic Hypersomnia Severity Scale. Neurology. 2019;92(15):e1754\u201362. https:\/\/doi.org\/10.1212\/wnl.0000000000007264.","journal-title":"Neurology"},{"issue":"7","key":"1262_CR35","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/sleep\/32.7.915","volume":"32","author":"ER Chasens","year":"2009","unstructured":"Chasens ER, Ratcliffe SF, Weaver TE. Development of the FOSQ-10: a short version of the Functional Outcomes of Sleep Questionnaire. Sleep. 2009;32(7):915\u20139.","journal-title":"Sleep"},{"issue":"2","key":"1262_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/104012371302500208","volume":"25","author":"GL Iverson","year":"2013","unstructured":"Iverson GL, Lam RW. Rapid screening for perceived cognitive impairment in major depressive disorder. Ann Clin Psychiatry. 2013;25(2):135\u201340.","journal-title":"Ann Clin Psychiatry"},{"issue":"5","key":"1262_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"Pharmacoeconomics"},{"key":"1262_CR38","unstructured":"Package GENEAread: package for reading binary files; 2024 [19 August 2025]. https:\/\/cran.r-project.org\/web\/packages\/GENEAread\/index.html."},{"key":"1262_CR39","unstructured":"Package GENEAclassify: Segmentation and classification of accelerometer data; 2024 [19 August 2025]. https:\/\/cran.r-project.org\/web\/packages\/GENEAclassify\/index.html."},{"issue":"7","key":"1262_CR40","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1152\/japplphysiol.00421.2014","volume":"117","author":"VT van Hees","year":"2014","unstructured":"van Hees VT, Fang Z, Langford J, Assah F, Mohammad A, da Silva IC, et al. Autocalibration of accelerometer data for free-living physical activity assessment using local gravity and temperature: an evaluation on four continents. J Appl Physiol (1985). 2014;117(7):738\u201344. https:\/\/doi.org\/10.1152\/japplphysiol.00421.2014.","journal-title":"J Appl Physiol (1985)"},{"issue":"6 Suppl","key":"1262_CR41","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.cvdhj.2021.10.002","volume":"2","author":"DM Frodi","year":"2021","unstructured":"Frodi DM, Kolk MZH, Langford J, Andersen TO, Knops RE, Tan HL, et al. Rationale and design of the SafeHeart study: development and testing of a mHealth tool for the prediction of arrhythmic events and implantable cardioverter-defibrillator therapy. Cardiovasc Digit Health J. 2021;2(6 Suppl):S11\u201320. https:\/\/doi.org\/10.1016\/j.cvdhj.2021.10.002.","journal-title":"Cardiovasc Digit Health J"},{"key":"1262_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae241","author":"DM Frodi","year":"2024","unstructured":"Frodi DM, Kolk MZH, Diederichsen SZ, Langford J, Knops RE, Tan HL, et al. Relationship between activity and sleep, as measured through a wearable accelerometer, and appropriate cardioverter defibrillator interventions: a prospective SafeHeart substudy. Europace. 2024. https:\/\/doi.org\/10.1093\/europace\/euae241.","journal-title":"Europace"},{"key":"1262_CR43","unstructured":"GENEActiv [product information]. Cambridgeshire: Activinsights; 2022."},{"issue":"9","key":"1262_CR44","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.5664\/jcsm.9326","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, Auger RR, Rowley JA, Hashmi SD, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895\u2013945. https:\/\/doi.org\/10.5664\/jcsm.9326.","journal-title":"J Clin Sleep Med"},{"key":"1262_CR45","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.sleep.2024.05.013","volume":"119","author":"MJ Thorpy","year":"2024","unstructured":"Thorpy MJ, Krahn L, Ruoff C, Foldvary-Schaefer N. Clinical considerations in the treatment of idiopathic hypersomnia. Sleep Med. 2024;119:488\u201398.","journal-title":"Sleep Med"},{"key":"1262_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.sleep.2025.02.019","volume":"29","author":"K Galu\u0161kov\u00e1","year":"2025","unstructured":"Galu\u0161kov\u00e1 K, Nev\u0161\u00edmalov\u00e1 S, P\u0159\u00edhodov\u00e1 I, Dost\u00e1lov\u00e1 S, Mazouchov\u00e1 A, \u0160onka K. Quality of life and its associates in narcolepsy 1 and 2 types and idiopathic hypersomnia. Sleep Med. 2025;29:31\u20139. https:\/\/doi.org\/10.1016\/j.sleep.2025.02.019.","journal-title":"Sleep Med"},{"issue":"11","key":"1262_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12111491","volume":"12","author":"S Nevsimalova","year":"2022","unstructured":"Nevsimalova S, Skibova J, Galuskova K, Prihodova I, Dostalova S, Maurovich-Horvat E, et al. Central disorders of hypersomnolence: association with fatigue, depression and sleep inertia prevailing in women. Brain Sci. 2022;12(11):1491. https:\/\/doi.org\/10.3390\/brainsci12111491.","journal-title":"Brain Sci"},{"key":"1262_CR48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.sleep.2021.01.031","volume":"80","author":"S Nevsimalova","year":"2021","unstructured":"Nevsimalova S, Susta M, Prihodova I, Maurovich Horvat E, Milata M, Sonka K. Idiopathic hypersomnia: a homogeneous or heterogeneous disease? Sleep Med. 2021;80:86\u201391.","journal-title":"Sleep Med"},{"issue":"5","key":"1262_CR49","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/archpsyc.1972.01750230066013","volume":"26","author":"B Roth","year":"1972","unstructured":"Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with \u201csleep drunkenness.\u201d Arch Gen Psychiatry. 1972;26(5):456\u201362. https:\/\/doi.org\/10.1001\/archpsyc.1972.01750230066013.","journal-title":"Arch Gen Psychiatry"},{"issue":"1-2","key":"1262_CR50","first-page":"108","volume":"15","author":"B Roth","year":"1981","unstructured":"Roth B. Idiopathic hypersomnia: a study of 187 personally observed cases. Int J Neurol. 1981;15(1\u20132):108\u201318.","journal-title":"Int J Neurol"},{"key":"1262_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.sleep.2017.10.005","volume":"45","author":"DT Plante","year":"2018","unstructured":"Plante DT. Nocturnal sleep architecture in idiopathic hypersomnia: a systematic review and meta-analysis. Sleep Med. 2018;45:17\u201324. https:\/\/doi.org\/10.1016\/j.sleep.2017.10.005.","journal-title":"Sleep Med"},{"key":"1262_CR52","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/NSS.S386021","volume":"15","author":"LD Schneider","year":"2023","unstructured":"Schneider LD, Stevens J, Husain AM, Ito D, Fuller DS, Zee C, et al. Symptom severity and treatment satisfaction in patients with idiopathic hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (ARISE). Nat Sci Sleep. 2023;15:89\u2013101.","journal-title":"Nat Sci Sleep"},{"issue":"3","key":"1262_CR53","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jsmc.2017.03.009","volume":"12","author":"LM Trotti","year":"2017","unstructured":"Trotti LM. Idiopathic hypersomnia. Sleep Med Clin. 2017;12(3):331\u201344. https:\/\/doi.org\/10.1016\/j.jsmc.2017.03.009.","journal-title":"Sleep Med Clin"},{"key":"1262_CR54","unstructured":"Casstevens C, Sterkel A, Graham CA, Price JA, Ginchereau Sowell F, Black J, Whalen M, Viswanathan HN, Wraight M, Farrell M, editors. A conceptual disease model of the symptoms and impacts of idiopathic hypersomnia from the patient perspective [poster 46]. Annual psych congress; October 29\u2013November 2, 2024; Boston, MA."},{"key":"1262_CR55","unstructured":"Household Data Annual Averages 47. Absences from work of employed full-time wage and salary workers by occupation and industry: U.S. Bureau of Labor Statistics; 2025 [18 August 2025]. https:\/\/www.bls.gov\/cps\/cpsaat47.htm."},{"issue":"6","key":"1262_CR56","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14(6):540\u20135.","journal-title":"Sleep"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01262-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01262-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01262-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:38:35Z","timestamp":1779802715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01262-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01262-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DT Plante is a consultant and advisory board member for Jazz Pharmaceuticals. He has also served as a consultant\/advisory board member for Alkermes, Centessa, Harmony Biosciences, and Takeda, advisory board member for Apnimed, and a consultant for Aditum Bio and Teva Pharmaceuticals (Australia). LD Schneider has received personal compensation for serving on advisory boards and speakers bureaus for Jazz Pharmaceuticals, Eisai, and Avadel. A Cairns, DA Nichols, DS Fuller, MT Kirby, JK Alexander, and M Whalen are full-time employees of Jazz Pharmaceuticals who, in the course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. S Akerman is a former full-time employee of Jazz Pharmaceuticals who, in the course of this employment, has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. TL Steininger is a former full-time employee and current contract worker for Jazz Pharmaceuticals who has received shares of Jazz Pharmaceuticals, plc. CM Ruoff has served as an advisory board member for Alkermes, Eisai, Jazz Pharmaceuticals, and Takeda and has received grant funding from Jazz Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All relevant data are provided within the manuscript and supporting files. Jazz has established a process to review requests from qualified external researchers for data from Jazz-sponsored clinical trials in a responsible manner that includes protecting patient privacy, assurance of data security and integrity, and furthering scientific and medical innovation. Additional details on Jazz Pharmaceuticals data sharing criteria and process for requesting access can be found at:\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study (\n                      \n                      identifier NCT05875974) was approved by institutional review boards or ethics committees at all sites (protocol approval number: Pro00071404; amendment approval numbers: MOD01782418, MOD01918961, MOD02130103) and was performed in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice and the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors had full access to all the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis. Statistical analysis: DS Fuller. All authors participated in the study. All were responsible for \u2013 study design,\u00a0acquisition, analysis, or interpretation of data; drafting of the manuscript; critical review and revision of the manuscript. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}